论文部分内容阅读
目的:观察新辅助化疗对Ⅱ、Ⅲ期鼻咽癌的近期疗效及生存率的影响。方法:69例初治NPC病人随机分组,观察组给予DDP+CF/5-FU化疗三个疗程后常规放疗,对照组给予常规放疗。结果:观察组CR率96%,总有效率(CR+PR)100%,2年无病生存率90%,2年总生存率92%;对照组CR61.8%,总有效率91.2%,2年无病生存率69%,2年总生存率73%。经统计学处理,两组CR率有显著性差异(P<0.01),总有效率无显著性差异(P>0.05),2年无病生存率及总生存率有显著性差异(P<0.01)。结论:新辅助化疗对提高Ⅱ、Ⅲ期鼻咽癌的近期疗效及生存率具有临床意义。
Objective: To observe the effect of neoadjuvant chemotherapy on the short-term efficacy and survival rate of stage Ⅱ and Ⅲ nasopharyngeal carcinoma. Methods: Ninety-nine patients with newly diagnosed NPC were randomly divided into three groups. The patients in the observation group received conventional radiotherapy after three cycles of chemotherapy with DDP + CF / 5-FU, while the control group received conventional radiotherapy. Results: The CR rate of the observation group was 96%, the total effective rate (CR + PR) was 100%, the 2-year disease-free survival rate was 90% and the 2-year overall survival rate was 92% 2-year disease-free survival rate of 69%, 2-year overall survival rate of 73%. There was a significant difference (P <0.01) between the two groups in CR rate (P <0.01), no significant difference in total effective rate (P> 0.05), 2-year disease-free survival rate and overall survival rate ). Conclusion: Neoadjuvant chemotherapy is of clinical significance in improving the short-term efficacy and survival rate of stage Ⅱ and Ⅲ nasopharyngeal carcinoma.